<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413930</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-TaTME-2018</org_study_id>
    <nct_id>NCT03413930</nct_id>
  </id_info>
  <brief_title>Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer</brief_title>
  <official_title>Single-center Prospective Randomized Controlled Study of the Transanal Total Mesorectal Excision Versus Laparoscopic Total Mesorectal Excision in Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the short-term and long-term results after transanal total
      mesorectal excision (TaTME) for the resection of mid and low rectal cancer compared with
      laparoscopic total mesorectal excision（LaTME）.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer (CRC) including rectal cancer is one of the most common gastrointestinal
      tumors, and its incidence is third in the world. At present，surgical treatments is the main
      means to cure CRC. Total mesorectal excision (TME) is the gold standard for rectal cancer
      surgery. Transanal total mesorectal excision (TaTME) was recently developed to overcome
      technical difficulties associated with LaTME and open TME. Most reports are retrospective
      studies. More studies, especially large-scale, randomized controlled trials are needed to
      establish the best indications for TaTME for mid and low rectal cancer.This is a
      single-center, open-label, non-inferiority, randomized controlled trial. A total of 120
      eligible patients will be randomly assigned to TaTME group and LaTME group at a 1:1 ratio. It
      will provide valuable clinical evidence for the objective assessment of the oncological
      safety，efficacy and potential benefits of TaTME compared with LaTME for mid and low rectal
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circumferential resection margin (CRM)</measure>
    <time_frame>14 days after surgery</time_frame>
    <description>Positive rate of circumferential resection margin (pathological assessment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completeness of mesorectum</measure>
    <time_frame>14 days after surgery</time_frame>
    <description>Pathological assessment of completeness of the TME specimen（complete, near</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node detection</measure>
    <time_frame>14 days after surgery</time_frame>
    <description>Lymph nodes harvested（numbers）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal safety margin</measure>
    <time_frame>14 days after surgery</time_frame>
    <description>Length of distal margin （millimeter，mm）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Operative time（minutes）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Estimated blood loss（milliliters，ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>1-30 days after surgery</time_frame>
    <description>Duration of hospital stay（days after surgery）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery course</measure>
    <time_frame>1-14 days after surgery</time_frame>
    <description>Time to first ambulation, flatus, liquid diet and soft diet （hours after surgery）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early morbidity rate</measure>
    <time_frame>30 days</time_frame>
    <description>Morbidity rate 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>1-3 days after surgery</time_frame>
    <description>Postoperative pain is recorded using the visual analog scale (VAS) pain score （0-10 points）tool on postoperative day 1, 2, 3 and the day of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months after surgery</time_frame>
    <description>3-year disease free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival rate</measure>
    <time_frame>60 months after surgery</time_frame>
    <description>5-year overall survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>TaTME</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mid or low rectal cancer undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LaTME</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transanal total mesorectal excision</intervention_name>
    <description>Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）</description>
    <arm_group_label>TaTME</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic total mesorectal excision</intervention_name>
    <description>Patients undergo Laparoscopic total mesorectal excision.</description>
    <arm_group_label>LaTME</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years &lt; age &lt; 80 years

          -  Body mass index (BMI) &lt;30 kg/m2

          -  Tumor located in mid and low rectum ( the lower border of the tumor is located distal
             to the peritoneal reflection)

          -  Pathological rectal carcinoma

          -  Clinically diagnosed cT1-3N0-2 M0 lesions according to the 7th Edition of AJCC Cancer
             Staging Manual with or without neoadjuvant therapeutic history

          -  Tumor size of 5 cm or less

          -  ECOG score is 0-1

          -  ASA score is Ⅰ-Ⅲ

          -  Informed consent

        Exclusion Criteria:

          -  Requiring a Mile's procedure

          -  Fecal incontinence

          -  History of inflammatory bowel disease

          -  Pregnant woman or lactating woman

          -  Severe mental disease

          -  Intolerance of surgery for severe comorbidities

          -  Previous abdominal surgery

          -  Emergency operation due to complication (bleeding, perforation or obstruction) caused
             by rectal cancer

          -  Requirement of simultaneous surgery for other disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yimei Jiang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospitla North</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ren Zhao, MD</last_name>
    <phone>0086-18917762018</phone>
    <email>rjzhaoren@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital North</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201821</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yimei Jiang, MD</last_name>
      <phone>0086-18121263247</phone>
      <email>crissi@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Simillis C, Hompes R, Penna M, Rasheed S, Tekkis PP. A systematic review of transanal total mesorectal excision: is this the future of rectal cancer surgery? Colorectal Dis. 2016 Jan;18(1):19-36. doi: 10.1111/codi.13151. Review.</citation>
    <PMID>26466751</PMID>
  </reference>
  <reference>
    <citation>Fernández-Hevia M, Delgado S, Castells A, Tasende M, Momblan D, Díaz del Gobbo G, DeLacy B, Balust J, Lacy AM. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg. 2015 Feb;261(2):221-7. doi: 10.1097/SLA.0000000000000865.</citation>
    <PMID>25185463</PMID>
  </reference>
  <reference>
    <citation>Deijen CL, Velthuis S, Tsai A, Mavroveli S, de Lange-de Klerk ES, Sietses C, Tuynman JB, Lacy AM, Hanna GB, Bonjer HJ. COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Surg Endosc. 2016 Aug;30(8):3210-5. doi: 10.1007/s00464-015-4615-x. Epub 2015 Nov 4.</citation>
    <PMID>26537907</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Ren</investigator_full_name>
    <investigator_title>Chief Physicion</investigator_title>
  </responsible_party>
  <keyword>TaTME</keyword>
  <keyword>Rectal cancer</keyword>
  <keyword>Laparoscopic Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

